Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France
Sylvie Deuffic‐Burban, Gérard Babany, Isabelle Lonjon‐Domanec, Pierre Deltenre, Valérie Canva‐Delcambre, Sébastien Dharancy, Alexandre Louvet, Françoise Roudot‐Thoraval, Philippe Mathurin – 29 October 2009 – Clinicians continue to raise questions concerning the necessity of treating chronic hepatitis C virus (HCV)‐infected patients with normal alanine aminotransferase (N‐ALT), in light of their slower progression to cirrhosis than patients with elevated alanine aminotraferase (E‐ALT).